Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-08

Clinical Trial Update: Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial of bapineuzumab in Alzheimer's disease was terminated; results were posted January 8, 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bapineuzumab (bapineuzumab)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-01-08